William Blair Issues Pessimistic Outlook for BMY Earnings

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Investment analysts at William Blair decreased their Q4 2024 earnings estimates for shares of Bristol-Myers Squibb in a report issued on Thursday, October 31st. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will earn $1.47 per share for the quarter, down from their prior estimate of $1.56. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $0.72 per share. William Blair also issued estimates for Bristol-Myers Squibb's Q1 2025 earnings at $1.73 EPS, Q2 2025 earnings at $1.91 EPS, Q3 2025 earnings at $2.03 EPS, FY2025 earnings at $7.46 EPS, FY2026 earnings at $7.15 EPS, FY2027 earnings at $7.42 EPS and FY2028 earnings at $6.59 EPS.

Other analysts have also recently issued reports about the company. Barclays upped their price target on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an "underweight" rating in a research note on Monday, October 7th. BMO Capital Markets lifted their price target on shares of Bristol-Myers Squibb from $53.00 to $57.00 and gave the stock a "market perform" rating in a research report on Friday. StockNews.com upgraded shares of Bristol-Myers Squibb from a "buy" rating to a "strong-buy" rating in a research report on Monday, July 29th. Citigroup lowered Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $75.00 to $55.00 in a report on Friday, October 25th. Finally, Cantor Fitzgerald restated a "neutral" rating and issued a $50.00 price target on shares of Bristol-Myers Squibb in a report on Friday, October 18th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of "Hold" and a consensus price target of $53.00.

Bristol-Myers Squibb Trading Up 2.1 %

NYSE BMY traded up $1.13 on Monday, reaching $55.45. The company had a trading volume of 10,772,444 shares, compared to its average volume of 14,467,169. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $56.20. The stock's 50 day moving average is $51.41 and its 200-day moving average is $46.61. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 2.86. The stock has a market cap of $112.42 billion, a price-to-earnings ratio of -15.45, a PEG ratio of 15.49 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.49 by $0.31. The firm had revenue of $11.89 billion for the quarter, compared to analysts' expectations of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.40%. The business's revenue for the quarter was up 8.4% on a year-over-year basis. During the same period last year, the firm earned $2.00 earnings per share.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 4.33%. The ex-dividend date was Friday, October 4th. Bristol-Myers Squibb's payout ratio is -66.85%.

Hedge Funds Weigh In On Bristol-Myers Squibb

Large investors have recently modified their holdings of the business. Reston Wealth Management LLC bought a new position in Bristol-Myers Squibb in the third quarter valued at approximately $25,000. Hollencrest Capital Management grew its stake in shares of Bristol-Myers Squibb by 61.3% in the third quarter. Hollencrest Capital Management now owns 492 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 187 shares in the last quarter. ESL Trust Services LLC acquired a new position in Bristol-Myers Squibb during the first quarter worth $27,000. Kennebec Savings Bank bought a new stake in Bristol-Myers Squibb during the third quarter worth $28,000. Finally, Valued Wealth Advisors LLC lifted its stake in Bristol-Myers Squibb by 1,168.1% in the third quarter. Valued Wealth Advisors LLC now owns 596 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 549 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.